Publication | Open Access

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence

VaccinationBreast OncologyBreast Cancer PatientsMedicineImmunologyClinical TrialsPrimary AnalysisVaccine TrialTherapeutic VaccineBreast CancerVaccine EfficacyOncologyCancer Research